欧盟对罕见病的监管观点:关注血浆蛋白相关疾病

{"title":"欧盟对罕见病的监管观点:关注血浆蛋白相关疾病","authors":"J. Kerr","doi":"10.3233/PPL-2009-0239","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":348240,"journal":{"name":"Pharmaceuticals, policy and law","volume":"129 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"EU regulatory perspective on rare diseases: Focus on plasma protein related disorders\",\"authors\":\"J. Kerr\",\"doi\":\"10.3233/PPL-2009-0239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":348240,\"journal\":{\"name\":\"Pharmaceuticals, policy and law\",\"volume\":\"129 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceuticals, policy and law\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/PPL-2009-0239\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceuticals, policy and law","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/PPL-2009-0239","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}